Professional-Grade Plant-Based Therapeutics
ProVEDA is the first company committed to providing natural therapeutic solutions scienficially proven and effective.
$1,499,998.40
Raise Dollar Amount
$9,999.60
Target Offering Amount
2025 PRODUCT ROLLOUT PLAN*
1st Quarter — Pain Relief
$367
Category Projection by 2031¹
2nd Quarter — Oral Care
$80
Category Projection by 2031²
3rd Quarter — Hair Growth
$11
Category Projection by 2030³
4th Quarter — Acne care
$14
Category Projection by 2032⁴
*The future rollout is dependent on available capital.
Co-Founders Track Record
Trusted and endorsed by Boomer Esiason, 14-Year NFL Quarterback
The testimonials presented are the opinions of the individuals providing them, and the individuals were not compensated. They may not represent the experience of all clients or investors and are not a guarantee of future performance or success. Boomer Esiason was compensated by ProVEDA Corporation in cash and stock as a spokesperson. Boomer Esiason is also an investor in ProVEDA Corporation and has financial or other interest that could affect the objectivity of his statements.
As seen in
Global pain relief market can reach $376+ billion by 2031
$367 billion
The global pain relief market was valued at approximately $196 billion in 2024 and is projected to grow at a CAGR of 8.10% from 2024 to 2031, potentially reaching $367 billion by 2031.¹ This market includes products to manage chronic pain, sports injuries, arthritis, and other types of physical discomfort.⁴
$259 billion
The plant-based pain relief segment is part of the $259 billion global wellness market, growing at an estimated 10-15% CAGR as consumers increasingly seek alternative, health-aligned therapies.⁵
$11 billion
The global sports medicine market was valued at $7.1 billion in 2021 and is expected to grow at a CAGR of 5.8% to reach $11.8 billion by 2030.⁶
6.5% CAGR
Demand for topical pain relief is slated to rise at a CAGR of 6.5% from 2024 to 2034. The pain relief market grew at a CAGR of 4.0% from 2019 to 2023.⁸
50 million Americans
With around 50 million Americans experiencing chronic pain, demand for effective pain management solutions is rising, driven by increasing awareness of alternative treatments and expected
rapid growth.⁷
Plant-based, science-backed
ProVEDA delivers professional-grade, safe, and effective topical products by combining traditional Ayurvedic ingredients with advanced plant stem cell technology—helping consumers live better lives every day with confidence and comfort.
Substantial evidence and research highlight the growing demand for natural, effective pain relief solutions in ProVEDA’s target market:
Concerns over side effects of synthetic drugs
The opioid crisis and risks of NSAIDs like ibuprofen have increased demand for non-addictive pain relief. Consumers seek safer options like ProVEDA’s plant-based formulations due to fewer side effects.
Rising demand for natural alternatives
A 2019 Nielsen report found nearly 75% of consumers prefer natural ingredients, driven by health concerns and side effects of synthetic drugs. The $4.5 billion Ayurvedic market reflects growing interest in holistic wellness.
Chronic pain is a widespread problem
With 50 million U.S. adults suffering from chronic pain, many seek alternatives to pharmaceuticals. Topical creams and natural remedies offer effective solutions without risks, addressing the need for safer pain management.
High-performance pain management needs
Traditional topical pain relief medications often cause adverse effects or fall short of providing lasting relief. College athletic programs, military personnel, and high-performance sectors are increasingly demanding effective, natural solutions.
Key growth drivers
of chronic pain
and alternative therapies
advancements
and fitness
healthcare professionals
Military and Athletics
Invest now in this unique cross-market opportunity
Why trust ProVEDA?
Innovative plant stem cell technology and a strong reputation in demanding markets position ProVEDA as a leader in natural, topical pain relief for both consumer and specialized sectors.
Increasing demand in multiple segments
ProVEDA targets the broader pain relief, sports recovery, and natural health segments, driven by growing demand for natural, non-invasive pain management solutions in sizable markets.
FDA-recognized active ingredients
ProVEDA’s use of FDA-recognized pain-relieving extracts like camphor and menthol sets it apart, building trust and credibility in a market where all-natural products often lack such regulatory validation.
PTA patent pending tech
ProVEDA uniquely provides a multi-layered pain relief experience by penetrating faster and deeper. Its proprietary Maximum Absorption Technology further enhances ProVEDA’s effectiveness and advantage.
Versatility across specialized groups
Beyond general consumers, ProVEDA targets specialized markets like the Department of Defense (DoD) and college athletic directors seeking non-invasive, fast-acting, long-lasting pain relief for military personnel and college athletes—without harmful side effects.
Potential for expansion into new markets
Dabur Research Foundation (DRF) has already developed and verified the safety & superior efficacy of ProVEDA’s next lines of “plant-based” products, including Oral Care, Hair Growth, and Acne Care.
Maximum Absorption Technology™
Our proprietary technology uses a precise three-phase process for faster, deeper penetration of active ingredients like menthol and camphor, offering faster, longer-lasting pain relief compared to ordinary creams—perfect for those needing consistent relief throughout the day.
Plant stem cell technology
ProVEDA prioritizes plant-based solutions over synthetic options, addressing the rising demand for cleaner health alternatives. Backed by research on over 70,000 medicinal plants and partnered with Dabur Research Foundation, we develop products free from chemical additives and synthetic formulations.
Ayurvedic medicine
ProVEDA’s Ayurvedic approach blends plant stem cells with traditional ingredients like menthol and camphor, drawing from a 5,000-year-old practice to reduce inflammation, support recovery, and promote overall wellness—catering to consumers seeking natural, holistic health solutions.
Professional-grade plant-based therapeutics
ProVEDA’s topical therapeutic formula combines scientifically selected plant extracts and essential oils, scientifically proven to enhance analgesic effects and relieve pain. Featuring a patent-pending delivery system, it has undergone rigorous safety and efficacy testing.
Invest in the future of Plant-based medicine today
Our team
Our seasoned founders bring extensive expertise in sales strategy, marketing, new ventures, and healthcare, providing strong leadership and strategic vision.
Maximizing companies’ value through global business development and strategic brand building.
Credited with developing and executing the company’s highly acclaimed branding strategy, including the naming and global launch of Windows.
Oversaw marketing strategies that strengthened the brand, ultimately leading to the company’s sale to Johnson & Johnson.
Post Microsoft, developed and sold mutiple companies, including Amaze Inc, iTRAVEL, and bEQUAL.
Scott Grizzle
Co-founder, Co-Chairman & Co-Chief Executive Officer
Maximizing shareholder value for companies by focusing on managing finance, marketing, and all legal aspects to a successful plan execution.
Implemented a successful sales channel to insurers and benefit providers and launched a successful DRTV campaign direct to consumers, ultimately achieving the sale of one of the pioneers in the telemedicine industry.
Developed technology solutions and services, such as casting and location scouting, for mutiple entertainment aspects, including feature film productions and project development.
Board of Directors
Leadership rooted in experience and insight.
Medical director
Dr. Michael Galitzer, ProVEDA Medical Director - A nationally recognized expert in Energy Medicine, integrative medicine, and bioidentical hormone replacement therapy (BHRT). For more than 40 years Dr. Galitzer has been a leading figure and innovator in the field of longevity, or anti-aging medicine, and provides cutting-edge medical services designed to reverse the aging process and regenerate the body.
Real users, Real results
See how our topical pain relief product is restoring the quality of life for people with muscle and joint aches and pains from arthritis, backaches, sprains, and strains.
By 2026, ProVEDA will become the most trusted brand in plant-based therapeutic products. This is our roadmap to success.
ProVEDA Max Pain Relief Cream
ProVEDA Max Pain Relief Cream has undergone rigorous safety and efficacy testing and is set to unlock new market opportunities in 2025, including those with the Department of Defense. All products are proprietary, and a patent has been filed.
ProVEDA Oral care
The global oral care market, valued at $53 billion in 2020, is projected to reach $80.74 billion by 2031. Benefits include anti-inflammatory properties, prevention of decay and gum disease, and teeth whitening.
Hair growth treatments
The global hair re-growth market is expected to reach $11.58 billion by 2030. Shampoos and conditioners lead the segment, while advancements in formulation now include specialized ingredients like plant extracts to boost efficacy and support hair growth.
Acne care
The global anti-acne market is projected to grow annually by 9.1% from 2023 to 2030. In 2022, creams and lotions made up 42% of revenue. Salicylic acid serums are popular for unclogging pores, reducing inflammation, and breaking down sebum.
Join us to unlock future of health and wellness
Join the discussion
FAQs
Here is all you need to know about becoming an investor. If you want to learn more about ProVEDA’s products, click here to find their FAQs.
Why invest in startups?
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
How much can I invest?
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
How do I calculate my net worth?
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Who can invest in a Regulation CF Offering?
Individuals over 18 years of age can invest.
What do I need to know about early-stage investing? Are these investments risky?
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
When will I get my investment back?
The Common Stock (the "Shares") of ProVEDA Corporation (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Can I sell my shares?
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
Exceptions to limitations on selling shares during the one-year lockup period:
In the event of death, divorce, or similar circumstance, shares can be transferred to:
The company that issued the securities
An accredited investor
A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)
What happens if a company does not reach their funding target?
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
How can I learn more about a company's offering?
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
What if I change my mind about investing?
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
How do I keep up with how the company is doing?
At a minimum, the company will be filing with the SEC and posting on it’s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
What relationship does the company have with DealMaker Securities?
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
Data references
- Grand View Research. (2023). Pain Relief Market Size, Share & Trends Analysis Report by Product (Topical, Oral), By Type (NSAIDs, Opioids), By Application (Chronic Pain, Acute Pain), By Region, And Segment Forecasts, 2023 - 2030.
- The global oral care industry is expected to reach $80.74 billion in 2031, up from $46.36 billion in 2023. Consumers' preferences for natural and organic oral care products, expanding awareness of the importance of oral health, and the increasing prevalence of dental illnesses are all driving market expansion. https://www.marketsandata.com/industry-reports/oral-care-market
- The hair growth supplement and treatment industry worldwide is expected to reach a projected revenue of $11.58 billion by 2030. A compound annual growth rate of 5.9% is expected of the worldwide hair growth supplement and treatment industry from 2024 to 2030. https://www.grandviewresearch.com/horizon/outlook/hair-growth-supplement-and-treatment-market-size/global
- The acne treatment market size was valued at $9.2 billion in 2021 and is projected to grow from $9.6 billion in 2022 to $14.44 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.6% during the forecast period (2023 - 2032). https://www.marketresearchfuture.com/reports/acne-treatment-market-5675
- Mordor Intelligence. (2023). Natural Pain Relief Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028).
- Research and Markets. (2023). Sports Medicine Market Size, Share & Trends Analysis Report by Product (Body Reconstruction Products, Body Support Products), By Application (Arthroscopy,Rehabilitation), By End-User (Athletes, Fitness Enthusiasts), And Segment Forecasts, 2023 - 2030.
- National Institutes of Health (NIH). (2021). Chronic Pain in the U.S.: A Comprehensive Study on the Impact of Chronic Pain on Daily Life.
- Fortune Business Insights. (2022). Topical Pain Relief Market Size, Share & COVID-19 Impact Analysis, By Product Type (Creams, Gels, Patches), By Application (Arthritis, Muscle Pain, Neuropathic Pain), By Distribution Channel (Hospital Pharmacies, Online Pharmacies), and Regional Forecast, 2021-2028.
Download our investors brief
Terms and Conditions.